title: Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment.
abstract: OBJECTIVE
  Antidepressants are a first-line treatment against neuropathic pain. We previously demonstrated that beta(2)-adrenoceptors are necessary for antidepressants to exert their anti-allodynic action. The aim of the present study was to assess whether beta(2)-adrenoceptor agonists could be sufficient to alleviate neuropathic allodynia.
  
  
  METHODS
  We used a murine model of neuropathy induced by unilateral sciatic nerve cuffing in C57BL/6J mice. We previously demonstrated that this animal model is sensitive to chronic, but not to acute, treatment with antidepressant drugs, which is clinically relevant. The mechanical allodynia was evaluated using the von Frey filaments.
  
  
  RESULTS
  We showed that chronic but not acute treatment with the beta-adrenoceptor agonists, bambuterol, isoprenaline, fenoterol, salbutamol, salmeterol, terbutaline or ritodrine suppressed mechanical allodynia. We confirmed that the action of these beta-adrenoceptor agonists was mediated through beta(2)-adrenoceptors by blocking it with intraperitoneal or intrathecal, but not intracerebroventricular or intraplantar, injections of the antagonist ICI118551. We also showed that chronic treatments with the beta-adrenoceptor antagonists, propranolol or ICI118551 did not suppress the allodynia.
  
  
  CONCLUSIONS
  Our data show that chronic treatment with beta-adrenoceptor agonists has the same antiallodynic properties as treatments with antidepressant drugs. This study was, however, conducted in an animal model, and a clinical validation will be required to confirm the value of the present findings in patients.
authors.affiliation: Institute of Cellular and Integrative Neurosciences, Centre National de la Recherche Scientifique, Strasbourg, France.
authors.forename: Nada
authors.initials: N
authors.lastname: Choucair-Jaafar
authors.forename: Ipek
authors.initials: I
authors.lastname: Yalcin
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Rodeau
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Waltisperger
authors.forename: Marie-José
authors.initials: MJ
authors.lastname: Freund-Mercier
authors.forename: Michel
authors.initials: M
authors.lastname: Barrot
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009437:Neuralgia / Q000188:drug therapy*; D010147:Pain Measurement; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C026777:ICI 118551; D011433:Propranolol